Exhibit 47

 

 

 

Grown Rogue Reports Fiscal 2023 Results

 

Revenue of $23.4M compared to $17.8M in 2022, an increase of 32%

 

Operating Cash Flow (OCF), before changes in working capital (WC), of $6.4M compared to $3.2M in 2022, an increase of 102%

 

Free Cash Flow1 (FCF) of $2.8M, after maintenance and growth investments of $3.5M

 

Announced a strategic advisory agreement with Goodness Growth Holdings to focus on improving quality, yields, and efficiencies in their Minnesota and Maryland operations

 

Announced entry into the attractive New Jersey market, with construction nearing completion and on track to be completed in Q2 2024, with sales expected in Q3 2024

 

Augmented New Jersey presence with a retail investment in collaboration with Bengal Capital to invest in the operations of an adult-use dispensary in West New York, New Jersey

 

Closed three tranches of convertible debentures for total gross proceeds of $8.0M

 

Medford, Oregon, February 29, 2024 – Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a craft cannabis company born from the amazing terroir of Oregon’s Rogue Valley, is pleased to report its audited 2023 results for the twelve months ended October 31, 2023. All financial information is provided in U.S. dollars unless otherwise indicated.

 

Fiscal 2023 Financial Summary ($USD Millions)

 

Fiscal 2023 Summary  2023   2022   +/- % 
Revenue   23.4    17.8    +32%
aEBITDA   7.6    5.1    +50%
aEBITDA %   32.7%   28.7%   +400 bps
OCF (Before Changes in WC)   6.4    3.2    +102%
OCF %   27.4%   17.9%   +950 bps  

 

Management Commentary

 

“We are pleased to announce another record year at Grown Rogue, highlighted by continued strong performance in our core markets of Oregon and Michigan, and in our new advisory agreement with Goodness Growth. Our year-over-year revenue and operating cash flow growth of 32% and 102%, respectively, shows our ability to profitably scale our business, our commitment to controlling costs through the growth cycle, and our focus on high quality cannabis products that delight our consumers,” said Obie Strickler, CEO of Grown Rogue. “Our operational performance combined with our ability to raise $8 million in reasonably priced convertible debt, underscores my confidence in our ability to be successful in New Jersey and beyond.”

 

 

 

 

“We are pleased with the construction progress in New Jersey and continue to believe this is an incredibly compelling return on our capital and capabilities. We are particularly excited to soon be bringing Oregon quality cannabis to the great people of New Jersey.

 

We also recently announced a retail investment in New Jersey to augment our cultivation facility in that market. We are excited to be collaborating with Nile and Bengal in this investment to allow us to expand outside of our core competency without taking too much capital or bandwidth, and continue to look for similar opportunities to sponsor aligned New Jersey retail in the future. This allows us access to shelf space for our branded flower products and earn additional profits within the highly attractive New Jersey market, while continuing our meticulous focus on producing affordable, craft-quality flower,” continued Mr. Strickler.

 

“Our 2024 corporate objectives remain unchanged from 2023: continued operational improvements, launching in New Jersey, and identifying and executing our next expansion project. We continue to refine our production, genetics, and efficiencies in our markets, drive increases in quality and yield for Goodness Growth, and gain market share in our new packaged products in Michigan and Oregon. We are also looking to expand into at least one additional market should we find an opportunity that fits our criteria, and we are in some advanced discussions on this front.

 

I want to personally thank the entire Grown Rogue team, our shareholders, and our customers for the continued support to help Grown Rogue achieve our goal of becoming the first nationally recognized craft cannabis company in the U.S.”

 

Oregon Market Highlights ($USD Millions)

 

Oregon  2023   2022   +/- % 
Revenue   11.0    8.9    +24%
aEBITDA   3.8    2.6    +49%
aEBITDA Margin %   34.7%   29.0%   +570 bps

 

#1 Flower brand and #3 brand overall in 2023, according to LeafLink’s MarketScape data, and #1 flower brand for ten consecutive quarters

 

Total harvested wet weights for the state of Oregon decreased 0% YoY for indoor, 3% YoY for mixed, and increased 1% YoY for outdoor, according to the Oregon Liquor and Cannabis Commission (OLCC) for calendar year 2023

 

Increased Oregon sungrown capacity with a lease option of 35 acres in Medford

 

Launched Grown Rogue and Yeti branded pre-roll packs that are exceeding internal expectations

 

2

 

 

Michigan Market Highlights ($USD Millions)

 

Michigan  2023   2022   +/- % 
Revenue   11.4    8.9    +28%
aEBITDA   5.1    3.9    +30%
aEBITDA Margin %   44.2%   43.8%   +40 bps

 

Released strain specific packaging and Yeti pre-rolls that has pushed pre-packaged product mix to 40% of sales in Q4 and has led to an increase in pricing and brand awareness

 

Sales in Michigan in December 2023 was a new record at $280M, and sales in 2023 were over $3.0B, the second market in the U.S to reach that milestone

 

Grown Rogue exercised its option and acquired 87% of Canopy Management, LLC resulting in its controlling interest in Golden Harvests, LLC

 

Michigan operations are through Golden Harvests, LLC.

 

Financial Statements and aEBITDA reconciliation

 

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION  October 31,
2023
   October 31,
2022
 
   $   $ 
ASSETS          
Current assets          
Cash and cash equivalents   8,858,247    1,582,384 
Accounts receivable (Note 18)   2,109,424    1,643,959 
Biological assets (Note 3)   1,566,822    1,199,519 
Inventory (Note 4)   4,494,257    3,131,877 
Prepaid expenses and other assets   392,787    352,274 
Total current assets   17,421,537    7,910,013 
Property and equipment (Note 8)   8,753,266    7,734,901 
Notes receivable (Notes 6.2.1 and 6.2.2)   1,430,526    - 
Warrants asset (Note 13.2)   1,361,366    - 
Intangible assets and goodwill (Note 9)   725,668    725,668 
Deferred tax asset (Note 20)   470,358    - 
TOTAL ASSETS   30,162,721    16,370,582 
           
LIABILITIES          
Current liabilities          
Accounts payable and accrued liabilities   2,359,750    1,821,875 
Current portion of lease liabilities (Note 7)   824,271    1,025,373 
Current portion of long-term debt (Note 10)   1,285,604    1,769,600 
Business acquisition consideration payable (Note 5)   360,000    360,000 
Unearned revenue   -    28,024 
Derivative liability (Notes 11.1.1, 11.2 and 11.2.1)   7,808,500    - 
Income tax payable   366,056    311,032 
Total current liabilities   13,004,181    5,315,904 
Lease liabilities (Note 7)   2,094,412    1,275,756 
Long-term debt (Note 10)   102,913    839,222 
Convertible debentures (Notes 11.1, 11.2 and 11.2.1)   2,412,762    - 
TOTAL LIABILITIES   17,614,268    7,430,882 
           
EQUITY          
Share capital (Note 12)   24,593,422    21,858,827 
Shares issuable (Note 12)   -    35,806 
Contributed surplus (Notes 13 and 14)   8,081,938    6,505,092 
Accumulated other comprehensive loss   (114,175)   (109,613)
Accumulated deficit   (20,996,449)   (21,356,891)
Equity atributable to shareholders   11,564,736    6,933,221 
Non-controlling interests (Note 23)   983,717    2,006,479 
TOTAL EQUITY   12,548,453    8,939,700 
TOTAL LIABILITIES AND EQUITY   30,162,721    16,370,582 

 

3

 

 
CONSOLIDATED STATEMENTS OF INCOME & LOSS AND COMPREHENSIVE INCOME & LOSS 

Years ended

October 31,

 
   2023   2022 
   $   $ 
Revenue          
Product sales (Note 2.5)   22,424,169    17,757,283 
Service revenue (Note 2.5.1)   929,016    - 
Total revenue   23,353,185    17,757,283 
           
Cost of goods sold          
Cost of finished cannabis inventory sold   (11,155,676)   (9,227,439)
Costs of service revenue   (308,641)   - 
Gross profit, excluding fair value items   11,888,868    8,529,844 
Realized fair value amounts in inventory sold   (2,573,151)   (3,685,338)
Unrealized fair value gain on growth of biological assets   3,355,797    3,278,572 
Gross profit   12,671,514    8,123,078 
Expenses          
Accretion expense   1,026,732    491,781 
Amortization of property and equipment   578,641    750,916 
General and administrative   6,465,877    5,852,236 
Share-based compensation   346,113    70,996 
Total expenses   8,417,363    7,165,929 
Income from operations   4,254,151    957,149 
Other income and (expense)          
Interest expense   (370,616)   (402,239)
Other income (expense)   441,487    (3,432)
Gain on debt settlement   -    453,858 
Unrealized loss on marketable securities   -    (333,777)
Unrealized loss on derivative liability   (4,563,498)   - 
Unrealized gain on warrants asset   129,113    - 
Loss on disposal of property and equipment   (182,025)   (6,250)
Total other expense, net   (4,545,539)   (291,840)
Gain (loss) from operations before taxes   (291,388)   665,309 
Income tax (Note 20)   (370,932)   (245,358)
Net income (loss)   (662,320)   419,951 
Other comprehensive income (items that may be subsequently reclassified to profit & loss)          
Currency translation loss   (4,562)   (19,235)
Total comprehensive income (loss)   (666,882)   400,716 
Gain (loss) per share atributable to owners of the parent – basic and diluted   (0.00)   0.00 
Weighted average shares outstanding – basic and diluted   172,708,792    170,632,611 
           
Net income (loss) for the period atributable to:          
Non-controlling interest   (129,279)   (27,507)
Shareholders   (533,041)   447,458 
Net income (loss)   (662,320)   419,951 
           
Comprehensive income (loss) for the period atributable to:          
Non-controlling interest   (129,279)   (27,507)
Shareholders   (537,603)   428,223 
Total comprehensive income (loss)   (666,882)   400,716 

 

4

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS 

Years ended

October 31,

 
   2023   2022 
   $   $ 
Operating activities          
Net income (loss)   (662,320)   419,951 
Adjustments for non-cash items in net income (loss):          
Amortization of property and equipment   578,641    750,916 
Amortization of property and equipment included in costs of inventory sold   1,757,672    1,102,688 
Unrealized gain on changes in fair value of biological assets   (3,355,797)   (3,278,572)
Changes in fair value of inventory sold   2,573,151    3,685,338 
Deferred income taxes   (470,358)   - 
Share-based compensation   -    21,264 
Stock option expense   344,593    96,649 
Accretion expense   1,026,732    491,781 
Loss on disposal of property and equipment   182,025    6,250 
Gain on debt settlement   -    (455,674)
Unrealized loss on marketable securities   -    333,777 
Loss on fair value of derivative liability   4,563,498    - 
Gain on warrants asset   (129,113)   - 
Effects of foreign exchange   (2,210)   918 
    6,406,514    3,175,286 
Changes in non-cash working capital (Note 15)   (677,163)   (1,171,111)
Net cash provided by operating activities   5,729,351    2,004,175 
           
Investing activities          
Purchase of property and equipment and intangibles   (1,456,782)   (1,111,283)
Cash advances and loans made to other parties   (1,430,526)   - 
Payments of acquisition payable   -    (2,000)
Net cash used in investing activities   (2,887,308)   (1,113,283)
           
Financing activities          
Proceeds from convertible debentures   8,000,000    - 
Proceeds from long-term debt   -    100,000 
Proceeds from private placement   -    1,300,000 
Repayment of long-term debt   (1,631,830)   (732,803)
Repayment of convertible debentures   (261,006)   - 
Payments of lease principal   (1,673,344)   (1,089,738)
Net cash provided by (used in) financing activities   4,433,820    (422,541)
           
Change in cash and cash equivalents   7,275,863    468,351 
Cash and cash equivalents, beginning   1,582,384    1,114,033 
Cash and cash equivalents, ending   8,858,247    1,582,384 

 

5

 

 

SEGMENTED aEBITDA – YEAR ENDED OCTOBER 31, 2023

 

   Oregon   Michigan   Services   Corporate   Consolidated 
Sales revenues   11,001,261    11,422,908    929,016    -    23,353,185 
Costs of goods sold, excluding fair value (“FV”) adjustments   (6,386,002)   (4,769,674)   (308,641)   -    (11,464,317)
Gross profit before fair value adjustments   4,615,259    6,653,234    620,375    -    11,888,868 
Net fair value adjustments   644,180    138,466    -    -    782,646 
Gross profit   5,259,439    6,791,700    620,375    -    12,671,514 
Operating expenses:                         
General and administration   1,535,791    1,985,636    -    2,944,450    6,465,877 
Depreciation and amortization   109,672    372,119    -    96,850    578,641 
Share based compensation   -    -    -    346,113    346,113 
Other income and expense:                         
Loss on sale of assets   (168,144)   (13,881)   -    -    (182,025)
Interest and accretion   (322,262)   (207,299)   -    (867,787)   (1,397,348)
Unrealized (loss) gain on derivative liability   -    -    -    (4,563,498)   (4,563,498)
Unrealized (loss) gain on warrants asset   -    -    -    129,113    129,113 
Other income and expense   410,751    14,043    -    16,693    441,487 
Net income (loss) before income tax   3,534,321    4,226,808    620,375    (8,672,892)   (291,388)
Income tax   -    690,725    -    (319,793)   370,932 
Net income after tax   3,534,321    3,536,083    620,375    (8,353,099)   (662,320)
Add back (deduct) from net income after tax:                         
Net FV adjustments in costs of goods sold   (644,180)   (138,466)   -    -    (782,646)
Amortization of property & equipment included in cost of sales   1,089,280    668,392    -    -    1,757,672 
Interest and accretion expense   322,262    207,299    -    867,787    1,397,348 
Amortization of property and equipment   109,672    372,119    -    96,850    578,641 
Share-based compensation   -    -    -    346,113    346,113 
Unrealized loss on derivative liability   -    -    -    4,563,498    4,563,498 
Unrealized gain on warrants asset   -    -    -    (129,113)   (129,113)
Income tax expense   -    690,725    -    (319,793)   370,932 
EBITDA   4,411,355    5,336,152    620,375    (2,927,757)   7,440,125 
Add back to EBITDA:                         
Compliance costs   -    -    -    83,747    83,747 
Costs associated with acquisition of Golden Harvests   -    -    -    110,000    110,000 
aEBITDA   4,411,355    5,336,152    620,375    (2,734,009)   7,633,872 
aEBITDA margin %   40.10%   46.71%   66.78%   -    32.69%

 

Free Cash Flow Reconciliation

 

Net cash provided by operating activities   5,729,351 
Purchase of property and equipment and intangibles   (1,456,782)
Cash advances and loans made to other parties   (1,430,526)
Free Cash Flow   2,842,043 

 

NOTES:

 

1.The Company’s “Free cash flow” metric is defined by cash flow from operations minus capital expenditures and expansion related advances
2.The Company’s “aEBITDA,” or “Adjusted EBITDA,” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines “EBITDA” as the Company’s net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities, the effects of fair-value accounting for biological assets and inventory, as well as other non-cash items and items not representative of operational performance as reported in net income (loss). Adjusted EBITDA is defined as EBITDA adjusted for the impact of various significant or unusual transactions. The Company believes that this is a useful metric to evaluate its operating performance.

 

6

 

 

NON-IFRS FINANCIAL MEASURES

 

EBITDA and aEBITDA are non-IFRS measures and do not have standardized definitions under IFRS. The Company has also provided unaudited pro-forma financial information, which assumes that closed and pending mergers and acquisitions in 2021 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2021. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.

 

About Grown Rogue

 

Grown Rogue International Inc. (CSE: GRIN | OTC: GRUSF) is a craft cannabis company operating in Oregon, Michigan, Minnesota, Maryland, and New Jersey, focused on delighting customers with premium flower and flower-derived products at fair prices. The Company’s roots are in Southern Oregon, where it has proven its capabilities in the highly competitive and discerning Oregon market. The Company’s passion for quality product and value, combined with a disciplined approach to growth, prioritizes profitability and return on capital without sacrificing quality. The Company’s strategy is to pursue capital efficient methods to expand into new markets, bringing craft-quality product at fair prices to more consumers. The Company also continues to make modest investments to improve outdoor craft cultivation capabilities in preparation for eventual interstate commerce. For more information, visit www.grownrogue.com.

 

FORWARD-LOOKING STATEMENTS

 

This press release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward- looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company and securing applicable

 

7

 

 

regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company’s public disclosure documents filed on Sedar.

 

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

 

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR+ at www.sedarplus.ca. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

 

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

 

8

 

 

For further information on Grown Rogue, please visit www.grownrogue.com or contact:

 

Obie Strickler

Chief Executive Officer

obie@grownrogue.com

 

Jakob Iote

Vice President of Investor Relations

jakeiote@grownrogue.com

(458) 226-2662

 

9